Blue Horseshoe Stocks: NFLX Review & More

Netflix, Inc. NFLX – Review

Nearly as often as we signal weekly options ideas, we also formulate longer term ones. Last month on the 12th, we entered our interest in the NFLX 01/25 $290-300 Calls into the log, and after an epic start to 2019, we’ve seen some really great moves.

NFLX stock alone, subsequent to our last alert, has traded for as little as 231.23 up to as high as yesterday’s new top mark of 357.22. That’s an incredible 54% jump in less than five weeks! What that move allowed our selected contracts to do has been nothing short of Earth-shattering.

$290 Calls – Range: 3.80-68.25 – Max Gain: 1696%
$292.50 Calls – Range: 3.28-49.22 – Max Gain: 1400%
$295 Calls – Range: 3.80-60.45 – Max Gain: 1491%
$297.50 Calls – Range: 3.47-59.76 – Max Gain: 1622%
$300 Calls – Range: 2.66-57.69 – Max Gain: 2069%
______

Fresh Options Ideas:
UAL Weekly $85-86 Calls
GT 03/01 $19-20 Calls


We also want to remind our readers to check out our PASO Report from Monday if you missed that, and stay tuned because we’ve got an exclusive interview with the company’s new Chief Operating Officer coming your way very soon!


Extended Watchlist:
PASO, HIPH, LXRX, GERN, TBLT, SCHW, TYME

Blue Horseshoe Stocks: TLRY Recap & More


Tilray, Inc. TLRY

Our first order of business this morning is to just provide a quick recap of our successful options idea from Friday, which we did not provide yesterday due to the release of our Special Report on PASO.(Check that report out if you missed it)

In Friday’s newsletter, we submitted the TLRY Weekly $92.50-95 Calls as potential day-trade candidates, and every single contract in that range provided huge multi-bag gain opportunities!

$92.50 Calls – Range: 2.10-8.30 – Max Gain: 295%
$93 Calls – Range: 2.00-9.20 – Max Gain: 360%
$93.50 Calls – Range: 1.80-5.00 – Max Gain: 178%
$94 Calls – Range: 2.14-9.83 – Max Gain: 359%
$95 Calls – Range: 1.21-8.85 – Max Gain: 631%


OPKO Health, Inc. OPK – Review

The last time we signaled OPK for observation was just a few weeks ago, on December 28th, just as the stock was gapping up off of its annual lows. Following that report, we’ve seen a couple weeks of steady gains, in an overall range from 2.84-3.935. That represents a solid 39% increase, and a good start to the 2019 calendar year.

We’ve also observed CEO Phillip Frost purchasing 15,000 shares out of the open market yesterday, near those highs. The next step for OPK would be to make a run at its 200DMA of 4.12, so we’ll continue to keep it on our radar in the days and weeks ahead.


Extended Watchlist:
PASO, DTEA, FTNW, KTOV, CVM

Blue Horseshoe Stocks: PASO Special Report

Patient Access Solutions, Inc. PASO – Special Report

We’re beginning this fresh trading week with a special report on a stock you’re not going to want to overlook. PASO (PASHealth) operates in the healthcare industry, for which it has adapted a wide array of services to provide solutions in a rapidly changing healthcare environment.

We are focusing upon PASO at an critical time in the company’s development, having only just announced an important step in a series of acquisitions that fall in line with its overall strategy of opening integrated health centers across New York State and in other regions of the country. Just last week, it was announced that the company had acquired a multi-specialty health and wellness facility.

It is the private practice of Dr. Donald Chiappetta in West Babylon, NY, a town on Long Island just a short drive from the company’s other facilities in Plainview NY.  The practice has been in operation for over two decades, and produces annual revenue exceeding $1.5M in serving, on average, more than 2000 patients on a monthly basis.

On the new union forged here in the new year, Dr. Chiappetta commented: “My staff and I are excited to join the Company. Integrating our practice and specialties with the Plainview facility will create a full service offering and offer our patients the ability to access our team of professionals across a larger geographic area.” (>>View Full PR)

Dr. Chiappetta has also been named Chief Operating Officer of PASO, responsible for managing day-to-day operations as well as facilitating growth both organically and through further strategic acquisitions. In addition to his private practice, he has also worked for both NFL, and Olympic athletes.

We are pleased to report that we will be conducting an exclusive interview with Dr. Chiappetta later this week via our Stock Traders Talk channel, so be sure you’re subscribed to our daily newsletter and keep an eye out for that announcement! In the meantime, take a look at why we’re interested in PASO from a technical standpoint on the chart snapshot below.


The recent bullish rise of PASO is sure to have raised some eyebrows, with considerably increased volume over the same time span.  The next key area of resistance for the stock to contend with sits at .0391. We’ll be looking for the PASO to test that area in the days and weeks ahead.
____

FRESH NEWS:
Just hitting the wires this morning is another update to the PASO newsreel.

COMMACK, NY, Jan. 14, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – Patient Access Solutions, Inc. (OTC PINK: PASO), a provider of technology and management solutions for the healthcare industry is proud to announce Dr. James Lederer will be joining the Company as the Director of Behavioral Health for the Group. Dr. Lederer will be based at the Plainview, NY Integrated Health facility. (>>View Full PR)
_____

For More Information on PASO Please Visit:
PASHEALTH.COM

Blue Horseshoe Stocks: Options Review & More

Options Review

Bed Bath & Beyond, Inc. BBBY – Yesterday morning’s premarket report contained an options idea for Bed Bath & Beyond following the company’s quarterly earnings report, the BBBY Weekly $13 & $13.50 Calls, and those plays both turned in fantastic intraday performances.

Regardless of which strike point was chosen, traders could have secured multi-bag profits on the day. The $13 Calls traded up from a low of .30 to a high of 1.30, for an increase of 333%, while the $13.50′s also crushed it with a huge 431% rip from .16-.85!
_______

Constellation Brands Inc. STZ -Just as Constellation stock got crushed to new lows in the premarket on Wednesday, we formulated a couple of longer-term options ideas, and wanted to provide updates on the activity there as well.

We were banking on STZ reversing off of those lows and beginning a recovery, and so far, it’s going quite well. Our targets were the  the STZ 02/01 $150-157.50 Calls and the 04/18 $160-170 Calls, and all seven sets of contracts in those ranges have been good for significant gain opportunities. These remain in play, and will remain on our watchlist going forward.

02/01 $150-157.50 Calls
$150 Calls – Range: 8.80-11.50 – Max Gain: 31%
$152.50 Calls – Range: 3.80-6.70 – Max Gain: 76%
$155 Calls – Range: 2.90-8.00 – Max Gain: 176%
$157.50 Calls – Range: 3.00-6.65 – Max Gain: 122%

04/18 $160-170 Calls

$160 Calls – Range: 5.50-10.83 – Max Gain: 97%
$165 Calls – Range: 4.00-8.01 – Max Gain: 101%
$170 Calls – Range: 2.78-6.07 – Max Gain: 118%
_____

Fresh Ideas:
GM Weekly $36-37.50 Calls
TLRY Weekly $92.50-95 Calls  


China SXT Pharma Inc SXTC

To wrap things up we wanted to go over the call we made on Monday morning in SXTC, which at the time had registered a low of 5.684. After steadily ramping up all week, yesterday the stock reached a new high of 23.35. That worked out to an incredible four-day swing of 311%

Cheers to anyone who caught this mover in Monday morning’s premarket report. It adds to an already impressive start for us here in 2019.


Extended Watchlist:
FTK, AQMS, MGEN, NAVB, SNSS, CFRX, TEUM

Blue Horseshoe Stocks: Form-4 Bottom Play

La Jolla Pharma Co. LJPC – Form-4 Bottom Play

One of the top scenarios we routinely scan for on a regular basis, is a Form-4 Bottom Play. Whenever we witness a stock trading at or near its annual lows being purchased in large amounts on the open market by its own directors, we can feel fairly certain that their confidence in a potential recovery is high.

LJPC is a fantastic example of this at the present time. We’ve just noticed more than 12M shares being purchased by a director in three separate transactions over the past few days, amounting to roughly $6.8M, or nearly five percent of LJPC’s total market cap. (>>View Transactions)

We’ll now treat this as any other bottom watch play, and monitor the stock for a recovery in coming sessions.


Kandi Technologies, Inc. KNDI

We signaled KNDI in yesterday morning’s extended watchlist, and the stock managed a solid move on the day for our first session of observation on the stock since early in the fall.

KNDI traded in a daily range from a low of 4.60 to 5.63, a modest but solid 22% intraday rise, and a good start on a more significant push. We’ll look for KNDI to test its previous resistance in the mid-$6 area going forward.


Fresh Options Ideas:
KBH 01/18 $22 & $23 Calls
BBBY Weekly $13 & $13.50 Calls